endometriosis semaglutide Injectable Shows Early Promise to Improve Fertility in Women with PMOS Ozempic (semaglutide) and vaginal health

Your clinician reviews risks, red flag symptoms, and alternatives if GLP-1s are not appropriate

Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).

Anti-aging and longevity powered by science Recharge & renew, from the inside out

Do not change on your own, because the strengths are not simply interchangeable